Galileo – Biotech Innovation Fund IM USD

Reference Data

ISIN LU2472219562
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund IM USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 126.81 USD 12.11.2024
Previous Price * 125.29 USD 11.11.2024
52 Week High * 166.77 USD 28.02.2024
52 Week Low * 100.05 USD 14.11.2023
NAV * 126.81 USD 12.11.2024
Issue Price * 126.81 USD 12.11.2024
Redemption Price * 126.81 USD 12.11.2024
Closing Price *
Indicative Minimum Price
Fund Assets *** 36,933,868
Unit/Share Assets *** 464,205
Trading Information SIX

Performance

YTD Performance -5.78% 29.12.2023
12.11.2024
YTD Performance (in CHF) -1.44% 29.12.2023
12.11.2024
1 month +5.88% 14.10.2024
12.11.2024
3 months +6.78% 12.08.2024
12.11.2024
6 months -2.05% 13.05.2024
12.11.2024
1 year +24.90% 13.11.2023
12.11.2024
2 years -21.56% 14.11.2022
12.11.2024
3 years -15.46% 31.05.2022
12.11.2024
5 years - -

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Krystal Biotech Inc 8.90%
Arcellx Inc 6.68%
4D Molecular Therapeutics Inc Ordinary Shares 4.44%
Iovance Biotherapeutics Inc 3.63%
Rocket Pharmaceuticals Inc 3.42%
Silence Therapeutics PLC ADR 3.36%
Stoke Therapeutics Inc 3.21%
Sarepta Therapeutics Inc 2.86%
Voyager Therapeutics Inc 2.65%
Q32 Bio Inc 2.54%
Last data update 30.04.2024

Cost / Risk

TER
TER date
Performance Fee ***
PTR
Max. Management Fee *** 1.25%
Ongoing Charges *** 1.57%
SRRI ***
SRRI date *** 31.10.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)